Vihren N Kolev Selected Research

PND 1186

8/2017	Inhibition of FAK kinase activity preferentially targets cancer stem cells.
5/2014	Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vihren N Kolev Research Topics

Disease

5	Neoplasms (Cancer) 01/2019 - 02/2014
2	Malignant Mesothelioma 05/2014 - 02/2014
1	Ovarian Neoplasms (Ovarian Cancer) 01/2019
1	Triple Negative Breast Neoplasms 08/2017
1	Breast Neoplasms (Breast Cancer) 08/2017
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2015
1	Neurofibromatosis 2 (Neurofibromatosis Type II) 05/2014
1	Ascites 02/2014

Drug/Important Bio-Agent (IBA)

2	Aldehyde DehydrogenaseIBA 01/2019 - 05/2014
2	PND 1186IBA 08/2017 - 05/2014
2	AsbestosIBA 05/2014 - 02/2014
1	PlatinumIBA 01/2019
1	Tyrosine (L-Tyrosine)FDA Link 01/2019
1	CateninsIBA 01/2019
1	defactinibIBA 08/2017
1	Phosphotransferases (Kinase)IBA 08/2017
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2015
1	VS-5584IBA 01/2015
1	Cisplatin (Platino)FDA LinkGeneric 01/2015
1	Neurofibromin 2 (Merlin)IBA 05/2014
1	Focal Adhesion Protein-Tyrosine KinasesIBA 05/2014

Therapy/Procedure

4	Drug Therapy (Chemotherapy) 01/2019 - 05/2014
1	Adjuvant Chemotherapy 01/2019
1	Oral Administration 08/2017
1	Injections 02/2014
1	Intraperitoneal Injections 02/2014